NovaDigm Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

【英語タイトル】NovaDigm Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA8013964)・商品コード:DATA8013964
・発行会社(調査会社):GlobalData
・発行日:2017年11月22日
・ページ数:22
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
NovaDigm Therapeutics Inc (NovaDigm) is a developer of immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial diseases. The company’s products include NDV-3 vaccines, ALS3 vaccines, vaccine clinical supplies, bacterial and fungal vaccine antigens, vaginal and bloodstream infections treatment vaccines, and fungal and bacterial pathogens vaccines. Its other products comprise vulvovaginal candidiasis vaccines, RWC treatment vaccines, skin and soft tissue infection treatment vaccines, nosocomial infection vaccines, venous catheters, endothelial cells, and feeding tubes, among others. NovaDigm offers services such as clinical trials, clinical discoveries, candidates development, preclinical studies, and invasive medical devices development services. The company’s products are used in treatment of skin, mucosal, and life-threatening systemic infections. NovaDigm is headquartered in Brookline, Massachusetts, the US.

NovaDigm Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
NovaDigm Therapeutics Acquires Rights to Beta-Mannan Trisaccharide Conjugate from University of Alberta, Louisiana State University School of Medicine and University of Toronto 10
NovaDigm Therapeutics Acquires Rights to Secreted Aspartyl Proteinase 2 from Pevion Biotech and Italian National Health Institute 11
Venture Financing 12
NovaDigm Therapeutics Raises US$14 Million In Series B Financing 12
NovaDigm Therapeutics Raises US$10 Million In Extended Series A Financing 14
NovaDigm Therapeutics Raises Additional US$4 Million In Series A Financing 15
Licensing Agreements 16
NovaDigm Therapeutics Enters into Licensing Agreement with Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center 16
NovaDigm Therapeutics Inc – Key Competitors 17
NovaDigm Therapeutics Inc – Key Employees 18
NovaDigm Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Clinical Trials 20
Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis 20
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NovaDigm Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
NovaDigm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NovaDigm Therapeutics Acquires Rights to Beta-Mannan Trisaccharide Conjugate from University of Alberta, Louisiana State University School of Medicine and University of Toronto 10
NovaDigm Therapeutics Acquires Rights to Secreted Aspartyl Proteinase 2 from Pevion Biotech and Italian National Health Institute 11
NovaDigm Therapeutics Raises US$14 Million In Series B Financing 12
NovaDigm Therapeutics Raises US$10 Million In Extended Series A Financing 14
NovaDigm Therapeutics Raises Additional US$4 Million In Series A Financing 15
NovaDigm Therapeutics Enters into Licensing Agreement with Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center 16
NovaDigm Therapeutics Inc, Key Competitors 17
NovaDigm Therapeutics Inc, Key Employees 18

★調査レポート[NovaDigm Therapeutics Inc-製薬・医療分野:企業M&A・提携分析] (コード:DATA8013964)販売に関する免責事項を必ずご確認ください。
★調査レポート[NovaDigm Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆